Clinical trials: Hypogonadism
Male Hypogonadism, Primary Hypogonadism
Pharmacokinetic Study to Determine Time to Steady-state
The purpose of the study is to confirm how long (i.e., how many days) it takes to reach steady-state when testosterone undecanoate is administered twice daily.
- Conditions
- Male Hypogonadism, Primary Hypogonadism, Secondary Hypogonadism
- Trial name
- NCT00911586
- Testing
- Testosterone undecanoate
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Clarus Therapeutics, Inc.
Secondary Hypogonadism, Sexual Dysfunction
Safety and Efficacy Study of Oral Fispemifene for the Treatment of Sexual Dysfunction in Hypogonadal Men
To evaluate the safety and efficacy of fispemifene in men with secondary hypogonadism and sexual side effects.
- Conditions
- Secondary Hypogonadism, Sexual Dysfunction, Erectile Dysfunction
- Trial name
- NCT02443090
- Testing
- fispemifene
- Where
- 16 sites in United States
- Volunteers
- 160 people
- Sponsor
- NexMed (U.S.A.), Inc. (subsidiary of Apricus Biosciences, Inc.)
Acquired Hypogonadotropic Hypogonadism, Obesity
A Multi-Center Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Body Composition and Metabolic Parameters With Diet and Exercise in Conjunction With Treatment With 12.5 mg or 25 mg Enclomiphene
The purpose of this study is to compare the effects of 12 months of treatment with enclomiphene 12.5 mg, 25 mg, or placebo capsules on body composition and metabolic parameters in overweight men with acquired hypogonadotropic…
- Trial name
- NCT02651688
- Testing
- Enclomiphene
- Where
- 5 sites in United States
- Volunteers
- 50 people
- Sponsor
- Repros Therapeutics Inc.
Adult Male Hypogonadism
A Multicenter Extension Trial to Evaluate the Safety of Testosterone Gel
This is a multicenter extension trial in adult hypogonadal males. The purpose of this study is to evaluate the safety of testosterone gel delivered using an applicator over an extended period of time.
- Trial name
- NCT01703741
- Testing
- Testosterone Gel (FE 999093)
- Where
- 18 sites in United States, Canada
- Volunteers
- 145 people
- Sponsor
- Ferring Pharmaceuticals
Hypogonadism
A Study to Evaluate the Potential for Interpersonal Transfer of Testosterone Following Single Dose Application
The hypotheses for this study is that there is no transfer of testosterone from male (donor) subjects to female (recipient) subjects when contact is made 2 hours post application of 2% Testosterone MD-Lotion® if the donor has a…
- Trial name
- NCT01172366
- Where
- Australia
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Acrux DDS Pty Ltd
Hypogonadism, Chronic Obstructive Pulmonary Disease
Efficacy and Safety of Fispemifene in the Treatment of Hypogonadal Men With Chronic Obstructive Pulmonary Disease That Are on Oral Glucocorticoid Therapy
The objective of the study is to assess and compare the preliminary efficacy, safety and tolerability of fispemifene 300 mg and placebo given once daily for 4 weeks in the treatment of hypogonadal men with chronic obstructive…
- Trial name
- NCT01061970
- Testing
- Fispemifene
- Volunteers
- 15 people
- Sponsor
- QuatRx Pharmaceuticals Company
Hypogonadism
Testogel® (Testosterone Gel 50mg/5g) in the Treatment of Male Hypogonadism
The purpose of this study is to evaluate the safety and efficacy of Testogel® 50mg/5g gel administered once daily (QD, morning dosing) compared to placebo administered once daily (QD, morning dosing), for 3 months, in hypogonadal…
- Trial name
- NCT01786473
- Testing
- Testogel 1%
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Laboratoires Besins International
Secondary Hypogonadism
An Open-Label, Single-Dose Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of Radiolabeled Androxal in Healthy Male Subjects After Oral Administration
The purpose of this study is to investigate the route(s) of elimination and mass balance of enclomiphene after oral administration of a single 25 mg (approximately equivalent to [(~]) 500 nanocurie [nCi]) dose of [14C]Androxal in…
- Trial name
- NCT02274181
- Testing
- Androxal
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Repros Therapeutics Inc.
Hypogonadism, Low Testosterone
A One Year Open Label Study for the Treatment of Hypogonadism (Low Testosterone) in Men Who Have Completed ZA-203
The purpose of this study is to determine the continued effects of Androxal on morning testosterone and reproductive status in men with secondary hypogonadism who have completed protocol ZA-203.
- Trial name
- NCT01386567
- Testing
- Androxal (enclomiphene citrate), Testim (topical testosterone)
- Where
- 8 sites in United States
- Volunteers
- 48 people
- Sponsor
- Repros Therapeutics Inc.
Hypogonadism
Pharmacokinetic Study of Testosterone Enanthate
Relative Bioavailability and Safety comparison of 3 formulations of Testosterone Enanthate.
- Trial name
- NCT01887418
- Testing
- QuickShot™ - 50 mg Treatment B, QuickShot™ - 100 mg Treatment A, Delatestryl 200 mg IM Treatment C
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Antares Pharma Inc.
Hypogonadism
A Clinical Trial to Evaluate the Pharmacokinetic Profiles and Safety of CKD-845
A clinical trial to evaluate the pharmacokinetic profiles and safety of CKD-845.
- Trial name
- NCT04673682
- Testing
- D309, CKD-845
- Where
- South Korea
- Volunteers
- 47 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Hypogonadism
NASOBOL in Hypogonadal Men in Comparison to Testosterone Levels in Normal Healthy Male Volunteers
In this study the serum concentration of testosterone and its main metabolite DHT will be measured in hypogonadal men using intranasal testosterone (Nasobol).
- Trial name
- NCT00647868
- Testing
- testosterone
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Acerus Pharmaceuticals Corporation
Hypogonadism
Efficacy and Safety of Testosterone Nasal Gel for Treating Hypogonadism in Men.
This is a phase III study for evaluation of Nasotestt efficacy compared to Androgel in the treatment of male participants with hypogonadism condition (reduced levels of testosterone) that have clinical indication of hormonal…
- Trial name
- NCT03281187
- Testing
- Nasotestt 5 mg, Androgel 50 mg
- Volunteers
- 228 people
- Sponsor
- FBM Industria Brasileira Ltda
Hypogonadism
Subcutaneous Testosterone Replacement Efficacy and Safety in Adult Men Diagnosed With Hypogonadism
Evaluation of efficacy and safety of testosterone enanthate administered subcutaneously using an auto-injector
- Trial name
- STEADY (NCT02159469)
- Testing
- Testosterone enanthate auto-injector
- Where
- 28 sites in United States
- Volunteers
- 150 people
- Sponsor
- Antares Pharma Inc.
Hypothalamic Obesity
A Study of Octreotide Depot vs Saline Control in Pediatric Hypothalamic Obesity Patients
The extension protocol is designed to allow those patients randomized to placebo in the core portion of the protocol to receive a 6 month treatment of open label octreotide and allow those patients randomized to octreotide who…
- Trial name
- NCT00171613
- Testing
- Octreotide
- Volunteers
- 32 people
- Sponsor
- Novartis
Hypogonadism, Testosterone Deficiency
An Efficacy and Safety Study of ABT-SLV176 for the Treatment of Hypogonadal Men
This is an open-study with a 26 week open label treatment period followed by an optional 26 week open label extension. The total treatment period will be 52 weeks.
- Trial name
- NCT02082197
- Testing
- ABT-SLV176
- Where
- 42 sites in United States
- Sponsor
- AbbVie
Hypogonadism, Cardiovascular Diseases
A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men
This is a double-blinded and placebo-controlled study of topical testosterone replacement therapy (TRT) in symptomatic hypogonadal men with pre-existing cardiovascular disease (CVD) or increased risk for CVD.
- Trial name
- TRAVERSE (NCT03518034)
- Testing
- AndroGel®
- Where
- 384 sites in United States, Puerto Rico
- Volunteers
- 5,246 people
- Sponsor
- AbbVie
Hypogonadotropic Hypogonadism
Efficacy and Safety of Corifollitropin Alfa (MK-8962) in Combination With Human Chorionic Gonadotropin (hCG) in Adolescent Males With Hypogonadotropic Hypogonadism (HH) (MK-8962-043)
The purpose of the study is to investigate whether corifollitropin alfa (MK-8962), administered alone for 12 weeks and then in combination with human chorionic gonadotropin (hCG) for 52 weeks, increases the testicular volume in…
- Trial name
- NCT03019575
- Testing
- Corifollitropin alfa, hCG
- Where
- 15 sites in Brazil, Denmark and 4 more
- Volunteers
- 17 people
- Sponsor
- Organon and Co
Secondary Hypogonadism
A Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment With 12.5 mg or 25 mg Androxal or AndroGel 1.62%
This is a Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men with Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment with the 12.5…
- Trial name
- NCT01993212
- Testing
- Androxal 12.5 mg or 25 mg, AndroGel 1.62%
- Where
- 8 sites in United States
- Volunteers
- 120 people
- Sponsor
- Repros Therapeutics Inc.
Hypogonadism, Male
Vogelxo(R) ABPM Study in Hypogandal Men
A Phase 4 ABPM study in Hypogonadal Men
- Trial name
- NCT04558567
- Testing
- Vogelxo
- Where
- 7 sites in United States
- Volunteers
- 122 people
- Sponsor
- Upsher-Smith Laboratories